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Dear Editor,
In a recent issue of the journal, Hurley and colleagues report a
five-year retrospective review of antibiotic treatment for chronic
Pseudomonas aeruginosa lung infection in 52 children attending
the Nottingham Paediatric Cystic Fibrosis Clinic. The review
showed no association between change in clinical end points
(FEV1, BMI or time to next exacerbation) and the in vitro
antibiotic susceptibility to the antibiotics administered [1]. This
timely study provides further evidence to question the clinical
value and routine use of conventional susceptibility testing
(disc diffusion, Etest, microtitre broth assay) on isolates of
P. aeruginosa from chronically infected patients with cystic
fibrosis (CF). The purpose of our letter is to stress additional
issues and distinctions, which are not addressed in the
Nottingham paper, but nevertheless are highly relevant to this
important aspect of CF management.
In addition to the impact of biofilm growth discussed by
Hurley and colleagues, explanations for the lack of concor-
dance between clinical outcome and susceptibility testing of
P. aeruginosa isolates include: variable susceptibility patterns
within the same or different colonial morphotypes from the
same sputum, the clinical impact of sub-inhibitory concentra-
tions of antibiotic, and the problem of testing a representative
bacterial sample from a variable population of P. aeruginosa
which can exceed 108 colony forming units/ml sputum [2,3].
The debate on the validity of susceptibility testing in the
management of CF lung infection has previously focused on
chronic infection and associated pulmonary exacerbations. The
distinction between early and chronic infections is important. Early
non-mucoid P. aeruginosa isolates are not associated with alginate
biofilms. Sampling is also not an issue since early isolates lack the
variable susceptibility patterns associated with chronic infection
[4]. Susceptibility in early isolates cannot however be assumed.
Although the majority of environmental and early clinical
P. aeruginosa are susceptible, some isolates are resistant even
using the higher breakpoints proposed for inhaled antibiotics [4].
To our knowledge, the relationship between susceptibility and
treatment of early P. aeruginosa infection has not been the
subject of a clinical study. Determining the reasons for initial
treatment failure is important as it is associated with a high risk of
subsequent exacerbations. The ELITE study did not consider
antibiotic susceptibility as a reason for success or failure in
pseudomonas eradication. The EPIC study was one of the largest1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2012.08.009studies of the treatment of early P. aeruginosa infection and
assessed inhaled tobramycin with or without oral ciprofloxacin.
While the incidence of treatment-emergent antibiotic resistance
was low, ranging from 0% to 4%, pre-treatment susceptibility
was not specifically addressed as a cause of treatment failure [5].
Debate on the validity of susceptibility testing must
therefore distinguish between the treatment of P. aeruginosa
causing early and chronic infections; and also between the use
of antibiotics to treat or to prevent exacerbations. Further
studies on the validity of susceptibility testing for early isolates
are required and should include redefined breakpoints appro-
priate for inhaled antibiotic formulations. The paper by Hurley
et al. is a very important contribution to the debate on the utility
of routine susceptibility testing for chronic infection [1]. Until
data suggest otherwise, however we suggest that it is prudent to
maintain susceptibility testing of early P. aeruginosa isolates.
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